Keywords
Last Name
Institution

Fred Lublin

TitlePROFESSOR
InstitutionMount Sinai
DepartmentNeurology
Address5 East 98th Street
Box 1138
New York NY 10029
Phone212-241-6854
Fax212-241-5333

     Bibliographic 
     selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Katz Sand IB, Lublin FD. Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneap Minn). 2013 Aug; 19(4 Multiple Sclerosis):922-43.
      View in: PubMed
    2. O'Connor PW, Lublin FD, Wolinsky JS, Confavreux C, Comi G, Freedman MS, Olsson TP, Miller AE, Dive-Pouletty C, Bégo-Le-Bagousse G, Kappos L. Teriflunomide reduces relapse-related neurological sequelae, hospitalizations and steroid use. J Neurol. 2013 Oct; 260(10):2472-80.
      View in: PubMed
    3. Lublin FD. MS as a gateway disease. J Neurol Sci. 2013 Oct 15; 333(1-2):73-5.
      View in: PubMed
    4. Weisfeld-Adams JD, Mehta L, Rucker JC, Dembitzer FR, Szporn A, Lublin FD, Introne WJ, Bhambhani V, Chicka MC, Cho C. Atypical Chédiak-Higashi syndrome with attenuated phenotype: three adult siblings homozygous for a novel LYST deletion and with neurodegenerative disease. Orphanet J Rare Dis. 2013; 8:46.
      View in: PubMed
    5. Lublin FD, Cofield SS, Cutter GR, Conwit R, Narayana PA, Nelson F, Salter AR, Gustafson T, Wolinsky JS. Randomized study combining interferon and glatiramer acetate in multiple sclerosis. Ann Neurol. 2013 Mar; 73(3):327-40.
      View in: PubMed
    6. McGraw CA, Lublin FD. Interferon beta and glatiramer acetate therapy. Neurotherapeutics. 2013 Jan; 10(1):2-18.
      View in: PubMed
    7. Narayana PA, Govindarajan KA, Goel P, Datta S, Lincoln JA, Cofield SS, Cutter GR, Lublin FD, Wolinsky JS. Regional cortical thickness in relapsing remitting multiple sclerosis: A multi-center study. Neuroimage Clin. 2012; 2:120-31.
      View in: PubMed
    8. Lublin FD. Relapses do not matter in relation to long-term disability: no (they do). Mult Scler. 2011 Dec; 17(12):1415-6.
      View in: PubMed
    9. O'Connor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N. Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology. 2011 May 31; 76(22):1858-65.
      View in: PubMed
    10. Repovic P, Lublin FD. Treatment of multiple sclerosis exacerbations. Neurol Clin. 2011 May; 29(2):389-400.
      View in: PubMed
    11. Phillips JT, Giovannoni G, Lublin FD, O'Connor PW, Polman CH, Willoughby E, Aschenbach W, Pace A, Hyde R, Munschauer FE. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler. 2011 Aug; 17(8):970-9.
      View in: PubMed
    12. Lublin FD, DeAngelis TM. Multiple sclerosis as a model neurologic disease. Mt Sinai J Med. 2011 Mar-Apr; 78(2):159-60.
      View in: PubMed
    13. Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, Fujihara K, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Montalban X, O'Connor P, Sandberg-Wollheim M, Thompson AJ, Waubant E, Weinshenker B, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011 Feb; 69(2):292-302.
      View in: PubMed
    14. Lünemann A, Tackenberg B, DeAngelis T, da Silva RB, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C. Impaired IFN-? production and proliferation of NK cells in multiple sclerosis. Int Immunol. 2011 Feb; 23(2):139-48.
      View in: PubMed
    15. Berger JR, Centonze D, Comi G, Confavreux C, Cutter G, Giovannoni G, Gold R, Hartung HP, Lublin F, Miravalle A, Montalban X, O'Connor P, Olsson T, Polman CH, Stuve O, Wolinsky JS, Ziemssen T. Considerations on discontinuing natalizumab for the treatment of multiple sclerosis. Ann Neurol. 2010 Sep; 68(3):409-11.
      View in: PubMed
    16. Morrow SA, O'Connor PW, Polman CH, Goodman AD, Kappos L, Lublin FD, Rudick RA, Jurgensen S, Paes D, Forrestal F, Benedict RH. Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler. 2010 Nov; 16(11):1385-92.
      View in: PubMed
    17. Kister I, Chamot E, Bacon JH, Niewczyk PM, De Guzman RA, Apatoff B, Coyle P, Goodman AD, Gottesman M, Granger C, Jubelt B, Krupp L, Lenihan M, Lublin F, Mihai C, Miller A, Munschauer FE, Perel AB, Teter BE, Weinstock-Guttman B, Zivadinov R, Herbert J. Rapid disease course in African Americans with multiple sclerosis. Neurology. 2010 Jul 20; 75(3):217-23.
      View in: PubMed
    18. Radue EW, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Rudick RA, Lublin FD, Weinstock-Guttman B, Wynn DR, Fisher E, Papadopoulou A, Lynn F, Panzara MA, Sandrock AW. Natalizumab plus interferon beta-1a reduces lesion formation in relapsing multiple sclerosis. J Neurol Sci. 2010 May 15; 292(1-2):28-35.
      View in: PubMed
    19. Straus Farber R, Devilliers L, Miller A, Lublin F, Law M, Fatterpekar G, Delman B, Naidich T. Differentiating multiple sclerosis from other causes of demyelination using diffusion weighted imaging of the corpus callosum. J Magn Reson Imaging. 2009 Oct; 30(4):732-6.
      View in: PubMed
    20. Rudick RA, Polman CH, Cohen JA, Walton MK, Miller AE, Confavreux C, Lublin FD, Hutchinson M, O'Connor PW, Schwid SR, Balcer LJ, Lynn F, Panzara MA, Sandrock AW. Assessing disability progression with the Multiple Sclerosis Functional Composite. Mult Scler. 2009 Aug; 15(8):984-97.
      View in: PubMed
    21. Rudick RA, Pace A, Rani MR, Hyde R, Panzara M, Appachi S, Shrock J, Maurer SL, Calabresi PA, Confavreux C, Galetta SL, Lublin FD, Radue EW, Ransohoff RM. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a. Neurology. 2009 Jun 9; 72(23):1989-93.
      View in: PubMed
    22. Mehta LR, Schwid SR, Arnold DL, Cutter GR, Aradhye S, Balcer LJ, Calabresi PA, Cohen JA, Cole PE, Glanzman R, Goelz S, Inglese M, Kapoor R, Kappos L, Kreitman R, Lublin FD, Mann A, Marrie RA, O'Looney P, Polman CH, Ravina BM, Reingold SC, Richert JR, Sandrock AW, Waubant E. Proof of concept studies for tissue-protective agents in multiple sclerosis. Mult Scler. 2009 May; 15(5):542-6.
      View in: PubMed
    23. Pandey K, Lublin FD. Clinically isolated syndrome and multiple sclerosis: rethinking the arsenal. Curr Treat Options Neurol. 2009 May; 11(3):193-202.
      View in: PubMed
    24. Hutchinson M, Kappos L, Calabresi PA, Confavreux C, Giovannoni G, Galetta SL, Havrdova E, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol. 2009 Mar; 256(3):405-15.
      View in: PubMed
    25. Goodman AD, Rossman H, Bar-Or A, Miller A, Miller DH, Schmierer K, Lublin F, Khan O, Bormann NM, Yang M, Panzara MA, Sandrock AW. GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology. 2009 Mar 3; 72(9):806-12.
      View in: PubMed
    26. Havrdova E, Galetta S, Hutchinson M, Stefoski D, Bates D, Polman CH, O'Connor PW, Giovannoni G, Phillips JT, Lublin FD, Pace A, Kim R, Hyde R. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol. 2009 Mar; 8(3):254-60.
      View in: PubMed
    27. Miller DH, Weinshenker BG, Filippi M, Banwell BL, Cohen JA, Freedman MS, Galetta SL, Hutchinson M, Johnson RT, Kappos L, Kira J, Lublin FD, McFarland HF, Montalban X, Panitch H, Richert JR, Reingold SC, Polman CH. Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler. 2008 Nov; 14(9):1157-74.
      View in: PubMed
    28. Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sørensen PS, Maas-Enriquez M, Sommerauer B, Hanna K. Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology. 2008 Jul 22; 71(4):265-71.
      View in: PubMed
    29. DeAngelis T, Lublin F. Multiple sclerosis: new treatment trials and emerging therapeutic targets. Curr Opin Neurol. 2008 Jun; 21(3):261-71.
      View in: PubMed
    30. Cutter GR, Lublin FD. Responsiveness and predictive values in PPMS: an uncertain message. Neurology. 2008 Mar 25; 70(13 Pt 2):1061-2.
      View in: PubMed
    31. Polman CH, Reingold SC, Barkhof F, Calabresi PA, Clanet M, Cohen JA, Cutter GR, Freedman MS, Kappos L, Lublin FD, McFarland HF, Metz LM, Miller AE, Montalban X, O'Connor PW, Panitch H, Richert JR, Petkau J, Schwid SR, Sormani MP, Thompson AJ, Weinshenker BG, Wolinsky JS. Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology. 2008 Mar 25; 70(13 Pt 2):1134-40.
      View in: PubMed
    32. DeAngelis T, Lublin F. Neurotherapeutics in multiple sclerosis: novel agents and emerging treatment strategies. Mt Sinai J Med. 2008 Mar-Apr; 75(2):157-67.
      View in: PubMed
    33. Rudick RA, Miller D, Hass S, Hutchinson M, Calabresi PA, Confavreux C, Galetta SL, Giovannoni G, Havrdova E, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol. 2007 Oct; 62(4):335-46.
      View in: PubMed
    34. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Lublin FD, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007 Oct 2; 69(14):1391-403.
      View in: PubMed
    35. Miller DH, Soon D, Fernando KT, MacManus DG, Barker GJ, Yousry TA, Fisher E, O'Connor PW, Phillips JT, Polman CH, Kappos L, Hutchinson M, Havrdova E, Lublin FD, Giovannoni G, Wajgt A, Rudick R, Lynn F, Panzara MA, Sandrock AW. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology. 2007 Apr 24; 68(17):1390-401.
      View in: PubMed
    36. Balcer LJ, Galetta SL, Calabresi PA, Confavreux C, Giovannoni G, Havrdova E, Hutchinson M, Kappos L, Lublin FD, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart WH, Wajgt A, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA. Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology. 2007 Apr 17; 68(16):1299-304.
      View in: PubMed
    37. Khalili K, White MK, Lublin F, Ferrante P, Berger JR. Reactivation of JC virus and development of PML in patients with multiple sclerosis. Neurology. 2007 Mar 27; 68(13):985-90.
      View in: PubMed
    38. Lublin FD. The incomplete nature of multiple sclerosis relapse resolution. J Neurol Sci. 2007 May 15; 256 Suppl 1:S14-8.
      View in: PubMed
    39. Phillips JT, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Polman CH, Lublin FD, Giovannoni G, Wajgt A, Lynn F, Panzara MA, Sandrock AW. Infusion-related hypersensitivity reactions during natalizumab treatment. Neurology. 2006 Nov 14; 67(9):1717-8.
      View in: PubMed
    40. Frohman EM, Havrdova E, Lublin F, Barkhof F, Achiron A, Sharief MK, Stuve O, Racke MK, Steinman L, Weiner H, Olek M, Zivadinov R, Corboy J, Raine C, Cutter G, Richert J, Filippi M. Most patients with multiple sclerosis or a clinically isolated demyelinating syndrome should be treated at the time of diagnosis. Arch Neurol. 2006 Apr; 63(4):614-9.
      View in: PubMed
    41. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2; 354(9):911-23.
      View in: PubMed
    42. Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006 Mar 2; 354(9):899-910.
      View in: PubMed
    43. Derwenskus J, Lublin FD. Use of interferon-beta in the treatment of multiple sclerosis. Adv Neurol. 2006; 98:257-71.
      View in: PubMed
    44. Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol. 2005 Dec; 58(6):840-6.
      View in: PubMed
    45. Lublin F. Multiple sclerosis trial designs for the 21st century: building on recent lessons. J Neurol. 2005 Nov; 252 Suppl 5:v46-53.
      View in: PubMed
    46. Lublin F. History of modern multiple sclerosis therapy. J Neurol. 2005 Sep; 252 Suppl 3:iii3-iii9.
      View in: PubMed
    47. Tullman MJ, Lublin FD. Combination therapy in multiple sclerosis. Curr Neurol Neurosci Rep. 2005 May; 5(3):245-8.
      View in: PubMed
    48. Lublin FD. Clinical features and diagnosis of multiple sclerosis. Neurol Clin. 2005 Feb; 23(1):1-15, v.
      View in: PubMed
    49. Tullman MJ, Oshinsky RJ, Lublin FD, Cutter GR. Clinical characteristics of progressive relapsing multiple sclerosis. Mult Scler. 2004 Aug; 10(4):451-4.
      View in: PubMed
    50. Cohen J, Cutter G, Lublin F, Schwid S. The MS Co-Operative REsearch (MS-CORE) group: an alternate approach to fostering multicenter studies. Mult Scler. 2004 Jun; 10(3):332-3.
      View in: PubMed
    51. Petkau AJ, White RA, Ebers GC, Reder AT, Sibley WA, Lublin FD, Paty DW. Longitudinal analyses of the effects of neutralizing antibodies on interferon beta-1b in relapsing-remitting multiple sclerosis. Mult Scler. 2004 Apr; 10(2):126-38.
      View in: PubMed
    52. Tullman MJ, Lublin FD. Evaluating multiple sclerosis. J Neurol Sci. 2004 Mar 15; 218(1-2):1-2.
      View in: PubMed
    53. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology. 2003 Dec 9; 61(11):1528-32.
      View in: PubMed
    54. Tullman MJ, Delman BN, Lublin FD, Weinberger J. Magnetic resonance imaging of meningoradiculomyelitis in early disseminated Lyme disease. J Neuroimaging. 2003 Jul; 13(3):264-8.
      View in: PubMed
    55. Lublin FD. When marketing and science intersect: do patients with MS benefit? Neurology. 2002 Nov 26; 59(10):1480-1.
      View in: PubMed
    56. Lublin FD. The diagnosis of multiple sclerosis. Curr Opin Neurol. 2002 Jun; 15(3):253-6.
      View in: PubMed
    57. Tullman MJ, Lublin FD, Miller AE. Immunotherapy of multiple sclerosis--current practice and future directions. J Rehabil Res Dev. 2002 Mar-Apr; 39(2):273-85.
      View in: PubMed
    58. Lublin FD. Therapeutic approaches to secondary progressive multiple sclerosis. Mult Scler. 2002 Feb; 8(1):88-90.
      View in: PubMed
    59. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 Jan 22; 58(2):169-78.
      View in: PubMed
    60. Faro SH, Mohamed FB, Tracy JI, Elfont RM, Pinus AB, Lublin FD, Koenigsberg RA, Chen CY, Tsai FY. Quantitative functional MR imaging of the visual cortex at 1.5 T as a function of luminance contrast in healthy volunteers and patients with multiple sclerosis. AJNR Am J Neuroradiol. 2002 Jan; 23(1):59-65.
      View in: PubMed
    61. Ben-Zacharia AB, Lublin FD. Palliative care in patients with multiple sclerosis. Neurol Clin. 2001 Nov; 19(4):801-27.
      View in: PubMed
    62. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, McFarland HF, Paty DW, Polman CH, Reingold SC, Sandberg-Wollheim M, Sibley W, Thompson A, van den Noort S, Weinshenker BY, Wolinsky JS. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul; 50(1):121-7.
      View in: PubMed
    63. Kalman B, Lublin FD. Spectrum and classification of inflammatory demyelinating diseases of the central nervous system. Curr Neurol Neurosci Rep. 2001 May; 1(3):249-56.
      View in: PubMed
    64. Lublin FD, Reingold SC. Placebo-controlled clinical trials in multiple sclerosis: ethical considerations. National Multiple Sclerosis Society (USA) Task Force on Placebo-Controlled Clinical Trials in MS. Ann Neurol. 2001 May; 49(5):677-81.
      View in: PubMed
    65. Whitaker JN, Wolinsky JS, Narayana PA, Bartolucci AA, Noseworthy JH, Lublin FD, Linde A, Gjörstrup P, Sullivan HC. Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol. 2001 Jan; 58(1):49-54.
      View in: PubMed
    66. Croul S, Lublin FD, Del Valle L, Oshinsky RJ, Giordano A, Khalili K, Ritchie CK. The cellular response of JC virus T-antigen-induced brain tumor implants to a Murine intra-ocular model. J Neuroimmunol. 2000 Jul 1; 106(1-2):181-8.
      View in: PubMed
    67. Wolinsky JS, Narayana PA, Noseworthy JH, Lublin FD, Whitaker JN, Linde A, Gjörstrup P, Sullivan HC. Linomide in relapsing and secondary progressive MS: part II: MRI results. MRI Analysis Center of the University of Texas-Houston, Health Science Center, and the North American Linomide Investigators. Neurology. 2000 May 9; 54(9):1734-41.
      View in: PubMed
    68. Noseworthy JH, Wolinsky JS, Lublin FD, Whitaker JN, Linde A, Gjorstrup P, Sullivan HC. Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology. 2000 May 9; 54(9):1726-33.
      View in: PubMed
    69. Kalman B, Lublin FD. The genetics of multiple sclerosis. A review. Biomed Pharmacother. 1999 Sep; 53(8):358-70.
      View in: PubMed
    70. Goodkin DE, Reingold S, Sibley W, Wolinsky J, McFarland H, Cookfair D, Lublin F. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: reporting extended results from phase III clinical trials. National Multiple Sclerosis Society Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Ann Neurol. 1999 Jul; 46(1):132-4.
      View in: PubMed
    71. Rice GP, Ebers GC, Lublin FD, Knobler RL. Ibuprofen treatment versus gradual introduction of interferon beta-1b in patients with MS. Neurology. 1999 Jun 10; 52(9):1893-5.
      View in: PubMed
    72. Cutter GR, Baier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J, Syndulko K, Weinshenker BG, Antel JP, Confavreux C, Ellison GW, Lublin F, Miller AE, Rao SM, Reingold S, Thompson A, Willoughby E. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999 May; 122 ( Pt 5):871-82.
      View in: PubMed
    73. Bramanti P, Sessa E, Rifici C, D'Aleo G, Floridia D, Di Bella P, Lublin F. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b. Neurology. 1998 Dec; 51(6):1720-3.
      View in: PubMed
    74. Lublin FD, Reingold SC. Combination therapy for treatment of multiple sclerosis. Ann Neurol. 1998 Jul; 44(1):7-9.
      View in: PubMed
    75. Joseph J, Lublin FD, Knobler RL. Modulation of T cell-endothelial adhesion by astrocyte conditioned medium. Glia. 1997 Dec; 21(4):408-12.
      View in: PubMed
    76. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Recommendations from the National Multiple Sclerosis Society Clinical Outcomes Assessment Task Force. Ann Neurol. 1997 Sep; 42(3):379-82.
      View in: PubMed
    77. Lublin FD, Reingold SC. Guidelines for clinical trials of new therapeutic agents in multiple sclerosis: relations between study investigators, advisors, and sponsors. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1997 Mar; 48(3):572-4.
      View in: PubMed
    78. Miller AE, Morgante LA, Buchwald LY, Nutile SM, Coyle PK, Krupp LB, Doscher CA, Lublin FD, Knobler RL, Trantas F, Kelley L, Smith CR, La Rocca N, Lopez S. A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis. Neurology. 1997 Feb; 48(2):312-4.
      View in: PubMed
    79. Kalman B, Lublin FD, Alder H. Impairment of central and peripheral myelin in mitochondrial diseases. Mult Scler. 1997 Jan; 2(6):267-78.
      View in: PubMed
    80. Kalman B, Rodriguez-Valdez JL, Bosch U, Lublin FD. Screening for Leber's hereditary optic neuropathy associated mitochondrial DNA mutations in patients with prominent optic neuritis. Mult Scler. 1997 Jan; 2(6):279-82.
      View in: PubMed
    81. Marini JC, Jameson BA, Lublin FD, Korngold R. A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. J Immunol. 1996 Oct 15; 157(8):3706-15.
      View in: PubMed
    82. Kalman B, Lublin FD, Alder H. Characterization of the mitochondrial DNA in patients with multiple sclerosis. J Neurol Sci. 1996 Sep 1; 140(1-2):75-84.
      View in: PubMed
    83. Rudick R, Antel J, Confavreux C, Cutter G, Ellison G, Fischer J, Lublin F, Miller A, Petkau J, Rao S, Reingold S, Syndulko K, Thompson A, Wallenberg J, Weinshenker B, Willoughby E. Clinical outcomes assessment in multiple sclerosis. Ann Neurol. 1996 Sep; 40(3):469-79.
      View in: PubMed
    84. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996 Apr; 46(4):907-11.
      View in: PubMed
    85. Kalman B, Alder H, Bosch UF, Lublin FD, Chatterjee D. The evolutionary relationship among Caucasian MS patients and controls. Mult Scler. 1996 Apr; 1(5):288-95.
      View in: PubMed
    86. Webster GF, Knobler RL, Lublin FD, Kramer EM, Hochman LR. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis. J Am Acad Dermatol. 1996 Feb; 34(2 Pt 2):365-7.
      View in: PubMed
    87. Miller DH, Albert PS, Barkhof F, Francis G, Frank JA, Hodgkinson S, Lublin FD, Paty DW, Reingold SC, Simon J. Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. US National MS Society Task Force. Ann Neurol. 1996 Jan; 39(1):6-16.
      View in: PubMed
    88. Lublin FD, Whitaker JN, Eidelman BH, Miller AE, Arnason BG, Burks JS. Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference. Neurology. 1996 Jan; 46(1):12-8.
      View in: PubMed
    89. Kalman B, Alder H, Lublin FD. Characteristics of the T lymphocytes involved in experimental allergic encephalomyelitis. J Neuroimmunol. 1995 Sep; 61(2):107-16.
      View in: PubMed
    90. Cambi F, Tartaglino L, Lublin F, McCarren D. X-linked pure familial spastic paraparesis. Characterization of a large kindred with magnetic resonance imaging studies. Arch Neurol. 1995 Jul; 52(7):665-9.
      View in: PubMed
    91. Tartaglino LM, Friedman DP, Flanders AE, Lublin FD, Knobler RL, Liem M. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology. 1995 Jun; 195(3):725-32.
      View in: PubMed
    92. Kalman B, Lublin FD, Alder H. Mitochondrial DNA mutations in multiple sclerosis. Mult Scler. 1995 Apr; 1(1):32-6.
      View in: PubMed
    93. Joseph J, Kim R, Siebert K, Lublin FD, Offenbach C, Knobler RL. Organ specific endothelial cell heterogeneity influences differential replication and cytopathogenicity of MHV-3 and MHV-4. Implications in viral tropism. Adv Exp Med Biol. 1995; 380:43-50.
      View in: PubMed
    94. Smith C, Birnbaum G, Carter JL, Greenstein J, Lublin FD. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994 Nov; 44(11 Suppl 9):S34-42; discussion S42-3.
      View in: PubMed
    95. Gonzalez CF, Swirsky-Sacchetti T, Mitchell D, Lublin FD, Knobler RL, Ehrlich SM. Distributional patterns of multiple sclerosis brain lesions. Magnetic resonance imaging--clinical correlation. J Neuroimaging. 1994 Oct; 4(4):188-95.
      View in: PubMed
    96. Paty D, Studney D, Redekop K, Lublin F. MS COSTAR: a computerized patient record adapted for clinical research purposes. Ann Neurol. 1994; 36 Suppl:S134-5.
      View in: PubMed
    97. Kalman B, Knobler RL, Lublin FD. Preferential but not exclusive T cell receptor V beta chain utilization of myelin basic protein and peptide-specific T cell clones in mice. Cell Immunol. 1994 Jan; 153(1):206-13.
      View in: PubMed
    98. Knobler RL, Greenstein JI, Johnson KP, Lublin FD, Panitch HS, Conway K, Grant-Gorsen SV, Muldoon J, Marcus SG, Wallenberg JC, et al. Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up. J Interferon Res. 1993 Oct; 13(5):333-40.
      View in: PubMed
    99. Jemison LM, Williams SK, Lublin FD, Knobler RL, Korngold R. Interferon-gamma-inducible endothelial cell class II major histocompatibility complex expression correlates with strain- and site-specific susceptibility to experimental allergic encephalomyelitis. J Neuroimmunol. 1993 Aug; 47(1):15-22.
      View in: PubMed
    100. Kalman B, Lublin FD, Lattime E, Joseph J, Knobler RL. Effects of staphylococcal enterotoxin B on T cell receptor V beta utilization and clinical manifestations of experimental allergic encephalomyelitis. J Neuroimmunol. 1993 Jun; 45(1-2):83-8.
      View in: PubMed
    101. Kálmán B, Lublin FD. Immunopathogenic mechanisms in experimental allergic encephalomyelitis. Curr Opin Neurol Neurosurg. 1993 Apr; 6(2):182-8.
      View in: PubMed
    102. Kalman B, Knobler RL, Lublin FD. T cell receptor V beta gene utilization in myelin basic protein specific clones from CXJ1 recombinant inbred mice. J Neuroimmunol. 1993 Mar; 43(1-2):191-4.
      View in: PubMed
    103. Lublin FD, Knobler RL, Kalman B, Goldhaber M, Marini J, Perrault M, D'Imperio C, Joseph J, Alkan SS, Korngold R. Monoclonal anti-gamma interferon antibodies enhance experimental allergic encephalomyelitis. Autoimmunity. 1993; 16(4):267-74.
      View in: PubMed
    104. Joseph J, Nunez M, Grun JL, Lublin FD, Hart MN, Knobler RL. Generation of an anti-mouse brain endothelial cell monoclonal antibody that recognizes 84-110 kDa and 36 kDa determinants that are upregulated by cytokines. Adv Exp Med Biol. 1993; 331:249-54.
      View in: PubMed
    105. Joseph J, Knobler RL, Lublin FD, Burns FR. Regulation of the expression of intercellular adhesion molecule-1 (ICAM-1) and the putative adhesion molecule Basigin on murine cerebral endothelial cells by MHV-4 (JHM). Adv Exp Med Biol. 1993; 342:389-91.
      View in: PubMed
    106. Joseph J, Grun JL, Lublin FD, Knobler RL. Cytokine induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). Adv Exp Med Biol. 1993; 342:443-8.
      View in: PubMed
    107. Joseph J, Grun JL, Lublin FD, Knobler RL. Interleukin-6 induction in vitro in mouse brain endothelial cells and astrocytes by exposure to mouse hepatitis virus (MHV-4, JHM). J Neuroimmunol. 1993 Jan; 42(1):47-52.
      View in: PubMed
    108. Swirsky-Sacchetti T, Field HL, Mitchell DR, Seward J, Lublin FD, Knobler RL, Gonzalez CF. The sensitivity of the Mini-Mental State Exam in the white matter dementia of multiple sclerosis. J Clin Psychol. 1992 Nov; 48(6):779-86.
      View in: PubMed
    109. Swirsky-Sacchetti T, Mitchell DR, Seward J, Gonzales C, Lublin F, Knobler R, Field HL. Neuropsychological and structural brain lesions in multiple sclerosis: a regional analysis. Neurology. 1992 Jul; 42(7):1291-5.
      View in: PubMed
    110. Lublin FD, Marini JC, Perreault M, Olender C, D'Imperio C, Joseph J, Korngold R, Knobler RL. Autoimmune inflammation of astrocyte transplants. Ann Neurol. 1992 May; 31(5):519-24.
      View in: PubMed
    111. Lublin FD. Susceptibility to experimental allergic encephalomyelitis in animal models of autoimmunity. Curr Opin Neurol Neurosurg. 1992 Apr; 5(2):182-7.
      View in: PubMed
    112. Knobler RL, Marini JC, Goldowitz D, Lublin FD. Distribution of the blood-brain barrier in heterotopic brain transplants and its relationship to the lesions of EAE. J Neuropathol Exp Neurol. 1992 Jan; 51(1):36-9.
      View in: PubMed
    113. Joseph J, Knobler RL, Lublin FD, Hart MN. Mouse hepatitis virus (MHV-4, JHM) blocks gamma-interferon-induced major histocompatibility complex class II antigen expression on murine cerebral endothelial cells. J Neuroimmunol. 1991 Sep; 33(3):181-90.
      View in: PubMed
    114. Jones SM, Streletz LJ, Raab VE, Knobler RL, Lublin FD. Lower extremity motor evoked potentials in multiple sclerosis. Arch Neurol. 1991 Sep; 48(9):944-8.
      View in: PubMed
    115. Joseph J, Knobler RL, Lublin FD, Hart MN. Regulation of MHC class I and II antigens on cerebral endothelial cells and astrocytes following MHV-4 infection. Adv Exp Med Biol. 1990; 276:579-91.
      View in: PubMed
    116. Joseph J, Knobler RL, Lublin FD, Hart MN. Differential modulation of MHC class I antigen expression on mouse brain endothelial cells by MHV-4 infection. J Neuroimmunol. 1989 May; 22(3):241-53.
      View in: PubMed
    117. Shy ME, Evans VA, Lublin FD, Knobler RL, Heiman-Patterson T, Tahmoush AJ, Parry G, Schick P, DeRyk TG. Antibodies to GM1 and GD1b in patients with motor neuron disease without plasma cell dyscrasia. Ann Neurol. 1989 May; 25(5):511-3.
      View in: PubMed
    118. Joseph J, Knobler RL, D'Imperio C, Lublin FD. Down-regulation of interferon-gamma-induced class II expression on human glioma cells by recombinant interferon-beta: effects of dosage treatment schedule. J Neuroimmunol. 1988 Nov; 20(1):39-44.
      View in: PubMed
    119. Joseph J, D'Imperio C, Knobler RL, Lublin FD. Down-regulation of gamma-interferon-induced class II expression of human glioma cells by recombinant beta-interferon. Ann N Y Acad Sci. 1988; 540:475-6.
      View in: PubMed
    120. Knobler RL, Brainard GC, Perreault M, D'Imperio C, Phenix P, Lublin FD. Immune effects of intracerebral infection with mouse hepatitis virus. Ann N Y Acad Sci. 1988; 540:642-4.
      View in: PubMed
    121. Barolat G, Knobler RL, Lublin FD. Trigeminal neuralgia in a patient with multiple sclerosis treated with high cervical spinal cord stimulation. Case report. Appl Neurophysiol. 1988; 51(6):333-7.
      View in: PubMed
    122. Knobler RL, Lublin FD, Streletz LJ, Zimmer M, Joseph J, D'Imperio C, Northrup B, Barolat G, Marcus SG. Intracerebral beta-interferon in brain tumor therapy. Monitoring cerebral function with compressed spectral analysis. Ann N Y Acad Sci. 1988; 540:573-5.
      View in: PubMed
    123. Brainard GC, Watson-Whitmeyer M, Knobler RL, Lublin FD. Neuroendocrine regulation of immune parameters. Photoperiod control of the spleen in Syrian hamsters. Ann N Y Acad Sci. 1988; 540:704-6.
      View in: PubMed
    124. Knobler RL, Lublin FD, Linthicum DS, Cohn M, Melvold RD, Lipton HL, Taylor BA, Beamer WG. Genetic regulation of susceptibility and severity of demyelination. Ann N Y Acad Sci. 1988; 540:735-7.
      View in: PubMed
    125. Lublin FD, Knobler RL, Marini J, Goldowitz D. Brain transplantation in genetic analysis of experimental allergic encephalomyelitis. Ann N Y Acad Sci. 1988; 540:252-4.
      View in: PubMed
    126. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin Immunol Immunopathol. 1987 Oct; 45(1):122-8.
      View in: PubMed
    127. Goldowitz D, Knobler RL, Lublin FD. Heterotopic brain transplants in the study of experimental allergic encephalomyelitis. Exp Neurol. 1987 Sep; 97(3):653-61.
      View in: PubMed
    128. Chanderkar LP, Shanker G, Knobler RL, Lublin FD, Paik WK, Kim S. Reduced S-adenosylmethionine:protein-lysine N-methyltransferase activity (protein methylase III) in shiverer mutant mouse brain. Neurochem Res. 1987 May; 12(5):445-9.
      View in: PubMed
    129. Brainard GC, Knobler RL, Podolin PL, Lavasa M, Lublin FD. Neuroimmunology: modulation of the hamster immune system by photoperiod. Life Sci. 1987 Mar 30; 40(13):1319-26.
      View in: PubMed
    130. Lublin FD, Knobler RL, Doherty PC, Korngold R. Relapsing experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Clin Exp Immunol. 1986 Dec; 66(3):491-6.
      View in: PubMed
    131. Jabourian Z, Lublin FD, Adler A, Gonzales C, Northrup B, Zwillenberg D. Hydrocephalus in Kartagener's syndrome. Ear Nose Throat J. 1986 Oct; 65(10):468-72.
      View in: PubMed
    132. Korngold R, Feldman A, Rorke LB, Lublin FD, Doherty PC. Acute experimental allergic encephalomyelitis in radiation bone marrow chimeras between high and low susceptible strains of mice. Immunogenetics. 1986; 24(5):309-15.
      View in: PubMed
    133. Kim S, Tuck M, Ho LL, Campagnoni AT, Barbarese E, Knobler RL, Lublin FD, Chanderkar LP, Paik WK. Myelin basic protein-specific protein methylase I activity in shiverer mutant mouse brain. J Neurosci Res. 1986; 16(2):357-65.
      View in: PubMed
    134. Lublin FD. Adoptive transfer of murine relapsing experimental allergic encephalomyelitis. Ann Neurol. 1985 Feb; 17(2):188-90.
      View in: PubMed
    135. Lublin FD. Relapsing experimental allergic encephalomyelitis. An autoimmune model of multiple sclerosis. Springer Semin Immunopathol. 1985; 8(3):197-208.
      View in: PubMed
    136. Lublin FD. Immunomodulation of relapsing experimental allergic encephalomyelitis. Neurology. 1984 Dec; 34(12):1615-7.
      View in: PubMed
    137. Stoll DB, Lublin F, Brodovsky H, Laucius JF, Patchefsky A, Cooper H. Association of subacute motor neuronopathy with thymoma. Cancer. 1984 Aug 15; 54(4):770-2.
      View in: PubMed
    138. Lublin FD. Role of myelin antigens in murine relapsing experimental allergic encephalomyelitis. J Clin Lab Immunol. 1984 Apr; 13(4):179-82.
      View in: PubMed
    139. Lublin FD, Tippett DL, Maurer PH. Central nervous system and blood lymphocytes in experimental allergic encephalomyelitis. J Clin Lab Immunol. 1983 Mar; 10(3):139-42.
      View in: PubMed
    140. Bakri YN, Lee JH, Lewis GC, Lublin FD, Danoff B. Meningeal carcinomatosis complicating gynecologic malignancies: a literature review and report of a case. Obstet Gynecol Surv. 1983 Jan; 38(1):1-5.
      View in: PubMed
    141. Check JH, Lublin FD, Mandel MM. Clomiphene as an anticonvulsant drug: A case report. Arch Neurol. 1982 Dec; 39(12):784.
      View in: PubMed
    142. Lublin FD. Delayed, relapsing experimental allergic encephalomyelitis in mice. Role of adjuvants and pertussis vaccine. J Neurol Sci. 1982 Nov-Dec; 57(1):105-10.
      View in: PubMed
    143. Berry RG, Chambers RA, Lublin FD. Syringoencephalomyelia (syringocephalus). J Neuropathol Exp Neurol. 1981 Nov; 40(6):633-44.
      View in: PubMed
    144. Lublin FD, Maurer PH, Berry RG, Tippett D. Delayed, relapsing experimental allergic encephalomyelitis in mice. J Immunol. 1981 Mar; 126(3):819-22.
      View in: PubMed
    145. Lublin FD, Maurer PH. Separation and properties of lymphocytes obtained from the central nervous system. J Clin Lab Immunol. 1980 Nov; 4(3):195-8.
      View in: PubMed
    146. Lublin FD, Tsairis P, Streletz LJ, Chambers RA, Riker WF, Van Poznak A, Duckett SW. Myokymia and impaired muscular relaxation with continuous motor unit activity. J Neurol Neurosurg Psychiatry. 1979 Jun; 42(6):557-62.
      View in: PubMed
    147. Duckett S, Cracco J, Lublin F, Scott T. Electron microscopical diagnosis of lipidosis with the use of rectal biopsy. Am J Dis Child. 1974 May; 127(5):704-5.
      View in: PubMed
    Lublin's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts
    _
    Co-Authors
    _
    Similar People
    _
    Same Department
     
    Mount Sinai Profiles is managed by Conduits - The Institutes for Translational Sciences at Icahn School of Medicine, supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences of the National Institutes of Health through Grant Number UL1TR000067